



Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

31st May, 2021

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Symbol: SAKAR

Dear Sir,

Sub: Outcome of Board Meeting and Submission of Audited Financial Results (Standalone & Consolidated) for the year ended on 31st March, 2021

We refer to our letter dated 25th May, 2021 informing the date of Meeting of the Board of Directors of the Company.

Please note that the Board of Directors in their meeting held today i.e. on 31st May, 2021, has approved the Audited Financial Results (Standalone & Consolidated) for the financial year 2020-21 ended on 31st March, 2021.


Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith:

1. Statement of Audited Financial Results (Standalone & Consolidated) for the year ended on 31st March, 2021.
2. Auditors' Report on the Audited Financial Results (Standalone & Consolidated).
3. Declaration to the effect that there is Unmodified Opinion with respect to Audited Financial Results (Standalone & Consolidated) for the year ended on 31st March, 2021.

Thanking you,

Yours faithfully,

for SAKAR HEALTHCARE LIMITED


SANJAY S. SHAH
MANAGING DIRECTOR
DIN: 01515296



Encl: As above



A. L. Thakkar & Co.
Chartered Accountants

A. L. THAKKAR
B.Com., L.L.B., F.C.A.

S. V. SHAH
B.Com., F.C.A.

Ahmedabad Office :

603-607, Aarya Epoch, Opp. Passport Seva Kendra, Nr. Vijay Cross
Roads, Navrangpura, Ahmedabad-380 009.

M. : 99780 34283, 70160 64684 • **Ph. :** (079) 48940856

E-mail : info@althakkar.com • **Website :** www.althakkar.com

STANDALONE AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF SAKAR HEALTHCARE LIMITED

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Sakar Healthcare Limited ("the Company") for the year ended 31st March, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone annual financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year then ended March 31, 2021.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended March 31, 2021 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were

operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the



preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results


Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other matter

The standalone annual financial results include the results for the quarter ended 31st March, 2021 and the corresponding quarter ended in the previous year being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year which were subject to limited review by us.

For A.L.Thakkar & Co.,
Chartered Accountants
FRN 120116W

Mitul Raval
Partner

ICAI Membership No. : 154789
UDIN : 21154759AAAABI2125



Place : Ahmedabad
Date : 31.05.2021

**STATEMENT OF STANDALONE AUDITED RESULTS
FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2021**

(Rs. In lakh)

Particulars (Refer Notes Below)	Quarter ended on			Year ended on	
	31-03-2021 (Audited)	31-12-2020 (Unaudited)	31-03-2020 (Audited)	31-03-2021 (Audited)	31-03-2020 (Audited)
1 Revenue from operations	2,168.15	2,679.34	1,826.04	9,473.93	8,298.03
2 Other income	41.38	26.60	102.79	117.53	201.68
3 Total Income (1+2)	2,209.53	2,705.94	1,928.83	9,591.46	8,499.71
Expenses					
a. Cost of Materials consumed	1,069.70	1,696.51	962.68	5,201.87	4,289.76
b. Purchases of stock-in-trade	-	-	-	-	-
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(192.00)	76.32	(123.05)	(90.63)	15.07
4 d. Employee benefits expense	319.35	354.55	354.09	1,325.51	1,212.92
e. Finance costs	43.42	79.81	64.70	248.25	225.26
f. Depreciation & amortisation expense	481.53	107.67	192.13	805.83	707.98
g. Other expenses	263.92	166.12	170.84	776.41	826.03
Total Expenses	1,985.92	2,480.98	1,621.39	8,267.24	7,277.02
5 Profit before exceptional items and tax (3-4)	223.61	224.96	307.44	1,324.22	1,222.69
6 Exceptional items	-	-	-	-	-
7 Profit before tax (5+6)	223.61	224.96	307.44	1,324.22	1,222.69
8 Tax expense:					
Current tax	34.60	39.51	11.86	317.75	251.00
Deferred tax	14.62	5.50	9.41	(62.73)	9.41
9 Profit for the period from continuing operations (7-8)	174.39	179.95	286.17	1,069.20	962.28
10 Profit from discontinuing operations before Tax	0.00	0.00	0.00	0.00	0.00
11 Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
12 Profit from Discontinuing operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00
13 Profit for the period (9+12)	174.39	179.95	286.17	1,069.20	962.28



Particulars (Refer Notes Below)	Quarter ended on			Year ended on	
	31-03-2021 (Audited)	31-12-2020 (Unaudited)	31-03-2020 (Audited)	31-03-2021 (Audited)	31-03-2020 (Audited)
14 Other Comprehensive Income					
Items that will not be reclassified subsequently to profit or loss					
Re-measurement gains/ (losses) on defined benefit plans	10.80	(1.46)	(5.83)	6.43	(5.83)
Income tax relating to items that will not be reclassified to profit or loss	(3.00)	0.41	1.62	(1.79)	1.62
Items that will be reclassified subsequently to profit or loss					
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Other Comprehensive Income, net of tax	7.80	(1.05)	(4.21)	4.64	(4.21)
15 Total Comprehensive Income for the period (13+14)	182.19	178.90	281.96	1,073.84	958.07
16 Paid-up equity shares capital (Face Value per share Rs. 10/-)	1,561.80	1,496.10	1,496.10	1,561.80	1,496.10
17 Reserves excluding Revaluation Reserves	-	-	-	8,284.37	6,635.87
18 Earnings Per Share of Rs. 10 each (for continuing operations)					
- Basic	1.17	1.20	1.88	6.88	6.40
- Diluted	1.17	1.20	1.88	6.88	6.40
Earnings Per Share of Rs.10 each (for discontinued operations)					
- Basic	-	-	-	-	-
- Diluted	-	-	-	-	-
20 Earnings Per Share of Rs. 10 each (for discontinued & continuing operations)					
- Basic	1.17	1.20	1.88	6.88	6.40
- Diluted	1.17	1.20	1.88	6.88	6.40



STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. In lakh)

Sr.No.	Particulars	As at 31-03-2021	As at 31-03-2020
		(Audited)	(Audited)
	ASSETS		
	Non-Current Assets		
	Property, plant and equipment	6,836.70	6,240.75
	Capital work-in-progress	4,892.21	1,309.53
	Other intangible Assets	73.02	328.00
1	Non-Current Financial Assets:		
	(i) Investments, Non-Current	1.00	1.00
	(ii) Trade receivables, Non-Current	-	-
	(iii) Loans, Non-Current	81.62	80.80
	Other Non-Current Assets	2,515.80	1,387.02
	Total Non-Current Assets	14,400.35	9,347.10
	Current Assets		
	Inventories	1,569.74	1,093.34
2	Current financial asset:		
	(i) Trade receivables, Current	1,237.42	823.40
	(ii) Cash and cash equivalents	8.04	29.59
	(iii) Loans, Current	7.72	7.57
	Other Current Assets	556.91	211.33
	Total Current Assets	3,379.83	2,165.23
	TOTAL ASSETS	17,780.18	11,512.33
	EQUITY AND LIABILITIES		
	Equity		
1	Equity share capital	1,561.80	1,496.10
	Other Equity	8,284.37	6,635.87
	Total Equity	9,846.17	8,131.97
	Liabilities		
	Non-Current Liabilities		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	3,845.02	1,247.22
	Provisions, Non-Current	79.31	69.76
	Deferred tax Liabilities (net)	682.78	639.58
	Total Non-Current Liabilities	4,607.11	1,956.56
	Current Liabilities		
	Current financial Liabilities:		
2	(i) Borrowings, Current	169.24	226.31
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	1,977.98	544.06
	(iii) Other Current financial Liabilities	245.46	196.21
	Other Current Liabilities	636.82	301.73
	Provisions	2.66	-
	Current tax Liabilities (Net)	294.74	155.49
	Total Current Liabilities	3,326.90	1,423.80
	Total Liabilities	7,934.01	3,380.36
	TOTAL EQUITY AND LIABILITIES	17,780.18	11,512.33



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The figures for quarter ended on 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2021 and the year to date figures upto the third quarter of the financial year.
2	The Company is operating only in one segment i.e. manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this the Company does not has any subsidiary/ associate.
4	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
5	Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 31 st May, 2021
7	The Statutory Auditors have carried out an audit of the above results for the financial year ended 31st March, 2021 and have issued an unmodified opinion on the same.
8	The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply- chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgments and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments and inventory, based on the information available to date, while preparing the Company's financial results as of and for the year ended March 31,2021

For SAKAR HEALTHCARE LIMITED

Date :31st May 2021

Place :Ahmedabad



SANJAY S SHAH
MANAGING DIRECTOR
(DIN : 01515296)

**STATEMENT OF CASH FLOWS FOR THE PERIOD
FROM 1ST APRIL, 2020 TO 31ST MARCH, 2021**

(Rs. In lakh)

Particulars	For the year ended on 31st March, 2021	For the year ended on 31st March, 2020
Profit before Taxes	1,324.22	1,222.70
Adjustments:		
Depreciation	805.83	707.98
Interest Expense	232.14	210.52
Provision for Doubtfull Debts	0.29	-
Changes in Other Equity	(73.49)	-
Other Non-Cash Adjstment	(74.55)	-
Changes in Working Capital		
Inventories	(476.40)	(407.70)
Financial assets		
- Trade receivables	(414.32)	126.90
- Loans and Advances	(0.15)	(7.57)
Other current assets	(345.59)	121.87
Financial assets		
- Loans and Advances	(0.82)	(55.36)
Financial liabilities		
- Borrowings	(57.07)	-
- Trade Payables	259.01	111.94
Other current liabilities	335.09	106.37
Provisions	16.85	18.37
Cashflow from Operating Activity before Taxes	1,531.04	2,156.02
Net Tax Paid	(72.57)	(277.24)
Net Cashflow from Operating Activity	1,458.47	1,878.78
Cashflow from Investing Activity		
Purchase of Property, Plant & Equipments	(3,554.56)	(1,297.89)
Purchase of Intangible Assets	-	(35.59)
Other non-current assets	(1,128.78)	(899.48)
Investment in Subsidiary	-	(1.00)
Net Cashflow from Investing Activity	(4,683.34)	(2,233.96)
Cashflow from Financing Activity		
Proceeds from issue of shares	788.40	0.44
Increase in Other Financial Liabilities	-	-
Proceeds / (Repayment) of Borrowings	2,605.39	520.99
Interest Paid	(190.47)	(173.34)
Net Cashflow from Financing Activity	3,203.32	348.09
Net Cash Inflow / (Outflow)	(21.55)	(7.09)
Opening Cash and Cash Equivalent	29.59	36.68
Closing Cash and Cash Equivalent	8.04	29.59

For SAKAR HEALTHCARE LIMITED



SANJAY S SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 31st May 2021
Place: Ahmedabad



Ahmedabad Office :

603-607, Aarya Epoch, Opp. Passport Seva Kendra, Nr. Vijay Cross
Roads, Navrangpura, Ahmedabad-380 009.

M. : 99780 34283, 70160 64684 • **Ph. :** (079) 48940856
E-mail : info@althakkar.com • **Website :** www.althakkar.com

CONSOLIDATED AUDITOR REPORT

TO THE BOARD OF DIRECTORS OF SAKAR HEALTHCARE LIMITED

1. We have reviewed the accompanying statement of Audited Consolidated Financial Results of **Sakar Healthcare Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax for the quarter ended 31.03.2021 and for the period from 01.04.2020 to 31.03.2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31.03.2021 and the corresponding period from 01.04.2020 to 31.03.2021, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:


- 1) Sakar Oncology Private Limited (wholly owned subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as



amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.L.Thakkar & Co.,
Chartered Accountants
FRN 120116W



Mitul Raval
Partner

ICAI Membership No. : 154759
UDIN : 21154759AAAABJ7586



Place : Ahmedabad
Date : 31.05.2021

**STATEMENT OF CONSOLIDATED AUDITED RESULTS
FOR THE YEAR ENDED ON 31ST MARCH, 2021**

(Rs. In lakh)

Particulars		Quarter ended on		Year ended on
		31-03-2021 (Audited)	31-12-2020 (Unaudited)	31-03-2021 (Audited)
(Refer Notes Below)				
1	Revenue from operations	2,168.15	2,679.34	9,473.93
2	Other income	41.38	26.60	117.53
3	Total Income (1+2)	2,209.53	2,705.94	9,591.46
	Expenses			-
	a. Cost of Materials consumed	1,069.70	1,696.51	5,201.87
	b. Purchases of stock-in-trade			
	c. Changes in inventories of finished goods, work-in-progress and	(192.00)	76.32	(90.63)
4	d. Employee benefits expense	320.30	354.55	1,326.46
	e. Finance costs	43.42	79.81	248.25
	f. Depreciation & amortisation expense	481.53	107.67	805.83
	g. Other expenses	263.92	166.12	776.41
	Total Expenses	1,986.87	2,480.98	8,268.19
5	Profit before exceptional items and tax (3-4)	222.66	224.96	1,323.27
6	Exceptional items			
7	Profit before tax (5-6)	222.66	224.96	1,323.27
8	Tax expense:			-
	Current tax	34.60	39.51	317.75
	Deferred tax	14.63	5.50	(62.73)
9	Profit for the period from continuing operations (7-8)	173.43	179.95	1,068.25
10	Profit from discontinuing operations before Tax	-	-	-
11	Tax expense of discontinuing operations	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-
	Profit for the period (9+12)	173.43	179.95	1,068.25
13	Attributable to owner of parent	173.43	179.95	1,068.25
	Attributable to Non-controlling interests	-	-	-



Particulars		Quarter ended on		Year ended on
(Refer Notes Below)		31-03-2021	31-12-2020	31-03-2021
		(Audited)	(Unaudited)	(Audited)
14	Other Comprehensive Income			
	<i>Items that will not be reclassified subsequently to profit or loss</i>			
	Re-measurement gains/ (losses) on defined benefit plans	10.79	(1.46)	6.43
	Income tax relating to items that will not be reclassified to profit or	(3.00)	0.41	(1.79)
	<i>Items that will be reclassified subsequently to profit or loss</i>			
	Income tax relating to items that will be reclassified to profit or			
	Other Comprehensive Income, net of tax	7.79	(1.05)	4.64
	Attributable to owner of parent	7.79	(1.05)	4.64
	Attributable to Non-controlling interests	-	-	-
15	Total Comprehensive Income for the period (13+14)	181.22	178.90	1,072.89
	Attributable to owner of parent	181.22	178.90	1,072.89
	Attributable to Non-controlling interests	-	-	-
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	1,561.80	1,496.10	1,561.80
17	Reserves excluding Revaluation Reserves	-	-	8,283.42
18	Earnings Per Share of Rs. 10 each			-
	(for continuing operations)			-
	- Basic	1.17	1.20	6.87
	- Diluted	1.17	1.20	6.87
19	Earnings Per Share of Rs. 10 each			-
	(for discontinued operations)			-
	- Basic	-	-	-
	- Diluted	-	-	-
20	Earnings Per Share of Rs. 10 each			-
	(for discontinued & continuing operations)			-
	- Basic	1.17	1.20	6.87
	- Diluted	1.17	1.20	6.87



STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

(Rs. In lakh)

Sr. No.	Particulars	As at 31-03-2021
		(Audited)
	ASSETS	
	Non-Current Assets	
	Property, plant and equipment	6,836.70
	Capital work-in-progress	4,892.22
	Other intangible Assets	73.02
1	Non-Current Financial Assets:	
	(i) Loans, Non-Current	81.62
	Other Non-Current Assets	2,523.36
	Total Non-Current Assets	14,406.92
	Current Assets	
	Inventories	1,569.73
	Current financial asset:	
2	(ii) Trade receivables, Current	1,237.42
	(iii) Cash and cash equivalents	8.25
	Current tax Assets (net)	556.92
	Other Current Assets	1,802.59
	Total Current Assets	3,372.32
	TOTAL ASSETS	17,779.24
	EQUITY AND LIABILITIES	
	Equity	
1	Equity share capital	1,561.80
	Other Equity	8,283.42
	Total Equity	9,845.22
	Liabilities	
	Non-Current Liabilities	
	Non-Current financial Liabilities:	
	(i) Borrowings, Non-Current	3,845.02
	Provisions, Non-Current	79.31
	Deferred tax Liabilities (net)	682.78
	Total Non-Current Liabilities	4,607.11
	Current Liabilities	
2	Current financial Liabilities:	
	(i) Borrowings, Current	169.24
	(ii) Trade payables, Current	
	(a) total outstanding dues of micro enterprises and small enterprises	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	1,977.98
	(iii) Other Current financial Liabilities	245.46
	Other Current Liabilities	636.83
	Provisions	2.66
	Current tax Liabilities (Net)	294.74
	Total Current Liabilities	3,326.91
	Total Liabilities	7,934.02
	TOTAL EQUITY AND LIABILITIES	17,779.24



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The figures for quarter ended on 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2021 and the year to date figures upto the third quarter of the financial year.
2	The Company is operating only in one segment i.e. manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given.
3	The consolidated audited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited.
4	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
5	Since this is first time that the company is required to prepare consolidated financial results, there are no reportable comparative figures.
6	Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods.
7	The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgments and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments and inventory, based on the information available to date, while preparing the Company's financial results as of and for the year ended March 31, 2021
8	The Statutory Auditors have carried out an audit of the above results for the financial year ended 31st March, 2021 and have issued an unmodified opinion on the same.
9	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 31st May, 2021

Date : 31st May 2021
Place : Ahmedabad

For SAKAR HEALTHCARE LIMITED



SANJAY S SHAH
MANAGING DIRECTOR
(DIN : 01515296)

**STATEMENT OF CONSOLIDATED CASH FLOWS FOR THE PERIOD
FROM 1ST APRIL, 2020 TO 31ST MARCH, 2021**

(Rs. In lakh)

Particulars	For the Year ended on 31st March 2021	For the Year ended on 31st March 2020
Profit before Taxes	1,323.27	1,222.69
Adjustments:		
Depreciation	805.83	707.98
Interest Expense	232.14	210.52
Provision for Doubtfull Debts	0.29	-
Changes in Other Equity	(73.49)	-
Other Non-Cash Adjustment	(74.55)	-
Changes in Working Capital		
Inventories	(476.40)	(407.70)
Financial assets		
- Trade receivables	(414.32)	126.90
Other current assets	(345.59)	121.87
Financial assets		
- Loans and Advances	(0.82)	(55.36)
Financial liabilities		
- Short term Borrowings	(57.07)	-
- Trade Payables	259.01	111.94
Other current liabilities	335.09	106.37
Provisions	16.85	18.37
Cashflow from Operating Activity before Taxes	1,530.25	2,163.59
Net Tax Paid	(72.58)	(277.24)
Net Cashflow from Operating Activity	1,457.67	1,886.35
Cashflow from Investing Activity		
Purchase of Property, Plant & Equipments	(3,554.57)	(1,297.88)
Purchase of Intangible Assets	-	(35.59)
Other Non-Current Assets	(1,128.78)	(907.06)
Net Cash flow from Investing Activity	(4,683.34)	(2,240.53)
Cashflow from Financing Activity		
Proceeds from issue of shares	788.40	0.44
Proceeds / (Repayment) of Borrowings	2,605.39	520.99
Interest Paid	(190.47)	(173.34)
Net Cashflow from Financing Activity	3,203.32	348.09
Net Cash Inflow / (Outflow)	(22.35)	(6.09)
Opening Cash and Cash Equivalent	30.59	36.68
Closing Cash and Cash Equivalent	8.24	30.59

For SAKAR HEALTHCARE LIMITED



SANJAY S SHAH
MANAGING DIRECTOR
(DIN: 01515296)

Date: 31st May 2021

Place: Ahmedabad



31st May, 2021

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Symbol: SAKAR

Dear Sir,

Sub: Declaration regarding Audit report with unmodified opinion with respect to Annual Audited Financial Results (Standalone & Consolidated) for the Financial Year ended 31st March, 2021


Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and SEBI Circular No.CIR/CFD/CMD/56/2016 dated 27th May, 2016, it is hereby declared and confirmed that Auditors' Reports obtained from M/s A. L. Thakkar & Co., Chartered Accountants on Annual Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended 31st March, 2021 have an unmodified opinion.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

for SAKAR HEALTHCARE LIMITED


SANJAY S. SHAH
MANAGING DIRECTOR
DIN: 01515296

